

Herbal Alternatives to Synthetic Drugs

SANA JAVED¹, AMMARA TARIQ¹, AROOJ FATIMA¹, FRIZA KHALIQ¹, MARYIAM ASMAT¹, FATIMA FAZAL¹, MALAIKA AZAM¹

¹Department of Pharmacy, The University of Faisalabad, Faisalabad, Pakistan
Corresponding authors: sanajaved.pharm@tuf.edu.pk

ABSTRACT: In light of growing drug resistance, unfavorable side effects, and the rising need for natural therapeutic options, herbal remedies have attracted attention on a global scale as safe and efficient substitutes for synthetic medications. The pharmacological potential of medicinal plants and their bioactive components is reviewed in this chapter, with a focus on how they can be used to treat chronic, inflammatory, metabolic, and viral disorders. Important mechanisms, such as antioxidant, antibacterial, immunomodulatory, and anti-inflammatory actions that underlie the medicinal benefits of herbal substances are discussed. Comparative analysis reveals that, in comparison to traditional medications, herbal compounds may provide better biocompatibility, less toxicity, and synergistic interactions. Standardization, quality control, efficacy validation, and regulatory acceptance issues continue to be major obstacles to wider clinical implementation despite their apparent advantages.

Keywords: Herbal Medicine, Phytotherapy, Synthetic Drugs

INTRODUCTION

Herbal medicine, a practice also known as phytotherapy is among the earliest and extensively followed methods of treatment and curing in human civilization. The history of herbal medicine is as ancient as civilization itself. Medicinal plants such as thyme and willow are registered in Sumerian clay tablets (~2600 BCE). Hundreds of botanical formulations are logged in The Ebers Papyrus of ancient Egypt. In Asia, Ayurveda, Traditional Chinese Medicine (TCM), and Unani systems, plants were extensively classified according to their humoral and dynamic effects (Fabricant and Farnsworth, 2001).

Plants, from primeval Mesopotamia to the present-day biopharmaceutical generation, have been used as humanity's chief source of medicine and inspiration for innovation in drug discovery. Almost around 80% of people, generally, are still making use of herbal remedies as part of their primary medical care, even when there has been a great improvement in synthetic chemistry and molecular pharmacology (Rausch et al., 2024). This dependence is largely common in underdeveloped countries, where availability, affordability, and cultural awareness support the usage of medicinal plants over synthetic drugs (Nissen, 2022). However, the acceptance of herbal supplements and nutraceuticals is rapidly growing even in technologically advanced nations, owing to the insight of natural products as safer and more integrated replacement to synthetic pharmaceuticals (Series, 2024).

The global healthcare prospect is entering a new era of integrative medicine, at which point herbal remedies are being reevaluated as supportive or substitutive options to common pharmaceuticals. The international herbal medication industry was valued at over USD 180 billion in 2022 and is estimated to exceed USD 300 billion by 2030, driven by user preference

towards natural and viable therapies (Hawks et al., 2021). Conversely, the synthetic drugs, which conventionally comprise of single-molecule compounds directed at particular targets, herbal preparations contain more than one component and have more than one target and are capable of simultaneously modulating several signaling pathways. This feature is especially relevant for complex, multifactorial situations like diabetes, cancer, cardiovascular diseases, and neurodegeneration, where multi agent therapy may offer therapeutic advantages (Thamizhoviya, 2025).

Synthetic drug development, while comprehensive, has revealed notable challenges. Many synthetic agents exhibit elevated strength but little safety perimeters, resulting in side effects such as toxicity in organs, hypersensitivity, and long-lasting metabolic disorders. The global dilemma of antibiotic resistance and chemoresistance in tumor studies has additionally called attention upon the constraints of the "one target-one drug" standard (Zeien et al., 2022). Herbal compounds, on the other hand, often carry out their pharmacological actions via complementary and versatile biological relationships, ameliorating cellular plasticity, homeostasis, and regenerating systems instead of entirely stamping out symptoms (Lee et al., 2022).

Furthermore, the diversity of chemicals present in medicinal plants provides a matchless reservoir of bioactive compounds, many of which act as a framework or epitome for modern drug development. *Salix alba* gave salicin, which became acetylsalicylic acid (aspirin); quinine, inspired antimalarial therapy obtained from *Cinchona officinalis*; morphine, an opioid analgesic was isolated from *Papaver somniferum*; and a key component of anticancer treatment, paclitaxel was procured from *Taxus brevifolii* (Stratton et al., 2015). These historical landmarks illustrate the under-way connection between synthetic pharmacology and natural

products. As a matter of fact, study shows that over 50% of medications came either directly or indirectly from natural sources that were approved between 1980 and 2020 (Newman and Cragg, 2020).

Other than efficacy, patient well-being and acceptability are the main intentions for the renewed consideration toward herbal substitutes. Synthetic drugs are specific and strong but they are often linked with undesirable drug reactions which are reckoned to be the reason of over 100,000 deaths in hospital per annum in the United States alone (Lazarou et al., 1998) On the contrary, standardized and appropriately used herbal preparations are likely to show fewer side effects and better biocompatibility due to their complex biochemical balance. For example, flavonoids and polyphenols extracted from plants exert pharmacological effects and additionally increase antioxidant function and brace endogenous cleansing systems, promoting a general sense of well-being (Gurley, 2025).

LIMITATIONS OF SYNTHETIC DRUGS

As synthetic drugs offer targeted, potent, and rapid acting treatment alternatives, they have notably improved in present day medicine. Although they are effective but they still have many disadvantages that have made scientists and healthcare providers to explore herbal replacements. These drawbacks include toxicology, resistance to drugs, cost of medicines, limited access, environmental effects, and the limited mechanistic nature of synthetic pharmaceuticals. An important drawback of synthetic drugs is the possibility of detrimental effects and organ toxicity (Zeien et al., 2022). These drugs generally show powerful physiological reactions as they are made up of pure chemicals of high concentration that are intended to focus on specific receptors or pathways. Due to this nature, it is likely that there is a greater chance of unwanted effects (Szumilak et al., 2021). For example, non-steroidal anti-inflammatory drugs (NSAIDs) act as anti-inflammatory drugs, but their long-term use can result in heart, kidney and stomach problems which may include blood thinning, nephrotoxicity, and gastrointestinal bleeding. Similarly, several chemotherapies may harm both healthy and tumor cells, causing serious harmful events like neuropathy, alopecia, and immune suppression. To manage these adverse effects there is a frequent requirement for additional medications and patient compliance.

Drug resistance is one of the major limitations. The increase in the appearance of resistant strains to antibiotics, antivirals, antimalarials, and antiparasitic drugs is due to their overuse and misuse. Microorganisms have a tendency of developing lifesaving mechanisms, for example, they can mutate drug targets. Another mechanism involves degradation of drugs by enzymes, activation of efflux pump, and the formation of biofilm (Jo et al., 2025). This has resulted to the appearance of multidrug-resistant pathogens such as Methicillin-Resistant Staphylococcus Aureus (MRSA) and drug-resistant tuberculosis. The development of synthetic drug cannot compete with the rapid emergence of resistance because many year are required for designing and approval of new drugs (El-Khoury et al., 2022).

Another barrier is the high cost involved in the development of a drug. It often takes many years and billions of dollars to market a single synthetic drug. The process of industrial production of drug includes their discovery, preclinical studies, clinical trials, regulatory assessment and manufacturing. These steps are the reason for high drug prices which make treatments beyond the reach of many patients, specifically in areas of lesser resources especially poor resources. On the other hand, medicinal plants can often be grown locally, harvested, and prepared at a much lesser cost (DiMasi et al., 2016).

Synthetic drug production is also affected by environmental issues. Chemical toxins, solvents, and byproducts are released into the environment from the pharmaceutical industries. In addition to this, residues of unmetabolized drugs which are excreted by humans and animals enter waterways and soil. These contaminants, encompassing hormones and antibiotics disrupt ecosystems, affecting aquatic species, and contributing to antimicrobial resistance (Aus der Beek et al., 2016).

A small change in dosage can lead to toxicity or reduction in effectiveness which means synthetic drugs often have narrow therapeutic windows. There are drugs that need close observation such as anticoagulants and anti-epileptics. This increases the load on clinicians, healthcare providers and patients. Though herbal medicines are not completely reliable but they often have broader safety margins due to their complex composition (Abdul-Aziz et al., 2020).

If we look at the mechanism of action, synthetic drugs often focus on single targets. This specificity is usually useful for acute conditions but it is less beneficial for chronic diseases such as diabetes, cancer, and autoimmune disorders which are multifactorial. Herbal medicines are more suitable for complete therapeutic strategies because they contain multiple bioactive compounds that regulate several pathways (Li et al., 2022).

Last but not the least, the adverse effects, taste, or complex dosing schedules associated with many synthetic drugs decrease the patient compliance. Poor compliance can lead to failure of treatment or worsening of disease. These limitations altogether emphasize the importance of investigating alternatives to herbal medicines, which may provide safer, more accessible, and multi-targeted therapeutic options. To enhance their benefits and ensure safe integration into modern healthcare, proper standardization and scientific validation of herbal medicines are important (Lee et al., 2016).

PHARMACOLOGICAL BASIS OF HERBAL ALTERNATIVES

Long before the formation of current pharmaceuticals, herbal medicines have been used for many years across various cultures, acting as the basis of primary healthcare systems. Progress in phytochemistry, molecular biology, and pharmacology in recent years, have uncovered the scientific basis of their conventional usage. The essence of the pharmacological superiority assigned to herbal alternatives in many therapeutic contexts is due to their being of a multi-

component, multi-target nature. The pharmacological basis of herbal medicines can be understood through their phytochemical composition of herbal medicines, their synergistic mechanisms, immunoregulatory and antimicrobial properties and scientific innovations that are continuously evolving aiming to improve their efficacy and safety (Mujahid et al., 2024).

Bioactive phytochemicals and their pharmacological significance

Phytochemicals perform crucial biological tasks which include shielding against pathogens, protection from ultraviolet (UV) light, and structural support. These compounds also produce remarkable therapeutic effects in humans. Alkaloids, flavonoids, terpenoids, phenolic acids, tannins, saponins, and glycosides are the major classes of phytochemicals (Kumar et al., 2023).

Alkaloids are compounds containing nitrogen and are known for their strong physiological activities. Many alkaloids have been efficiently incorporated into current medicine such as quinine which acts as an antimalarial, morphine as a potent analgesic, berberine as an antimicrobial agent, and vincristine as an anticancer drug. Their powerful biological activity shows that secondary metabolites of plants can match or exceed synthetic drugs in strength while providing more diversified pharmacodynamics (Kumar et al., 2023).

Quercetin, kaempferol, and catechins are flavonoids that are plentiful in fruits, vegetables, and medicinal herbs and have antioxidant, anti-inflammatory, antiallergic, antiviral, and cardioprotective properties (Wang et al., 2012). Moreover, caffeic and rosmarinic acids are phenolic acids which assist in resisting oxidative stress by targeting free radicals and modulating inflammatory cascades (Yang et al., 2013). Artemisinin from *Artemisia annua*, is a highly potent terpenoid that has shown powerful antimalarial activity transforming the treatment of malaria globally (Zheng et al., 2024).

Digitalis is a glycoside that has cardiac properties and regulates the function of here. Furthermore, saponins kill and control microbes, decrease the cholesterol levels, and regulate immune system (Xiao et al., 2025). Tannins by binding to proteins and inhibiting adhesion of pathogens contribute to constricting and antimicrobial activity (Huang et al., 2024).

Synergistic and multi-target mechanisms

Synthetic medicines usually act on a single molecular target, whereas herbal medicines contain many chemicals that act collectively to control various biochemical pathways at the same time. This synergy leads to increase in therapeutic efficacy and minimize the adverse effects (Karimi et al., 2015).

For instance, the healing actions of turmeric, *Curcuma longa*, are not only due to curcumin but also attributed to demethoxycurcumin, bisdemethoxycurcumin, and volatile oils such as turmerones (Shahrajabian and Sun, 2024). These compounds, together, increase absorption, stretch the half-life of curcumin, and widen its anti-inflammatory effects.

Similarly, combined action of gingerols, shogaols, zingerone, and various terpenes derived from ginger is responsible for its analgesic and anti-inflammatory properties (Ayustaningwarno et al., 2024).

The mode of action that focuses more than one target is particularly useful for chronic and complicated diseases including diabetes, cancer, cardiovascular disorders, and neurodegenerative conditions (Roy et al., 2024). For example, herbal antidiabetic formulations are often involved in the improvement of insulin sensitivity, reduction of oxidative stress, inhibition of carbohydrate-digesting enzymes, modulation of inflammatory signaling, and regulation of lipid metabolism which are the functions that no single synthetic drug can achieve alone (Roy et al., 2024).

Withania somnifera (ashwagandha) and *Panax ginseng* are the herbs that work through restorative mechanisms. They improve the body's resistance to stress and support hormonal balance (Gómez Afonso et al., 2023). Polyherbal formulations which are commonly used in Ayurveda and Traditional Chinese Medicine (TCM), are purposefully designed to utilize mutual interactions between multiple herbs to augment their therapeutic uses and minimize their toxicity (Kaur et al., 2024).

Immunomodulatory and anti-inflammatory actions

One of the most important actions of herbal remedies is regulation of immune system. Herbs help to regulate the immune response of body by either improving weakened immune function or suppressing excessive immune activation.

Some herbs increase immune function by increasing the activity of macrophages, natural killer cells, lymphocytes, and cytokines. These include Echinacea, Astragalus, and garlic. These plants support the body to fight better against infections and recover better from immunosuppressed states by stimulating congenital and acquired immunity (Stevenson et al., 2005).

Chief inflammatory mediators are curbed by anti-inflammatory herbs such as turmeric, ginger, Boswellia, and green tea. Curcumin is responsible for suppressing transcription factors like nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B), managing the regulation of inflammatory proteins such as cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF- α), and interleukin-6 (IL-6). Frankincense produces boswellic acids which inhibit 5-lipoxygenase and reduce the synthesis of leukotriene, alleviating inflammatory conditions such as arthritis and inflammatory bowel disease (Shao-Ling et al., 2009).

There is a central role of oxidative stress in inflammation and chronic diseases. Resveratrol from grapes, epigallocatechin-3-gallate (EGCG) from green tea, and anthocyanins from berries are herbal antioxidants which neutralize free radicals, protect cellular structures, and regulate redox-sensitive signaling pathways. These effects are responsible for the reduction of inflammation, improvement of

cellular repair, and betterment of overall health (Shahcheraghi et al., 2023).

Antimicrobial and anti-parasitic activities

Many medicinal herbs have useful antimicrobial, antiviral, antifungal, and anti-parasitic functions. Their mechanisms of action are very different from synthetic drugs due to which the chances of development of resistance are very low. Allicin obtained from garlic is involved in the disruption of cell walls of microbes, inhibition of enzyme action and prevention of formation of biofilm. Neem, *Azadirachta indica*, demonstrates a broad range of antimicrobial activity through compounds like azadirachtin and nimbidin. Oregano oil is rich in carvacrol and thymol and it effectively causes bacterial membranes lysis. It has also exhibited its action against strains resistant to antibiotics (Singh et al., 2025).

Antiviral properties are exhibited by turmeric, ginger, and licorice. This includes inhibition of viral replication and enhancement of mechanisms of host defense. Berberine present in Berberi's species, shows strong activity against bacteria, protozoa, fungi, and viruses. This makes it a valuable substitute areas where antimicrobial resistance is high (Tillhon et al., 2012).

There are many parasitic infections such as malaria which have also shown sensitivity to herbal compounds. Artemisinin from *Artemisia annua* continues to be one of the potent antimalarial substances and is the primary basis of artemisinin-based combination therapies (ACTs), responsible for a significant reduction of mortality due to malaria worldwide (O'Neill et al., 2010).

Pharmacokinetics, bioavailability and safety considerations

The pharmacokinetic actions of herbal medicines which include absorption, distribution, metabolism, and excretion are affected by both chemistry of plant and methods of their formulation (Bhattaram et al., 2002). Some phytochemicals poorly exhibit bioavailability because of their low solubility, rapid metabolism or little intestinal absorption (Rombolà et al., 2020). Curcumin is an example. It has low oral bioavailability even then its efficacy can be increased with the help of nano-formulations, other chemicals like piperine, or carriers which are lipid-based (Shoba et al., 1998).

Herbal drugs are natural but "natural" does not ensure safety. There are certain herbs which contain toxic compounds or which can interact with synthetic drugs and change their absorption or metabolism. Cytochrome P450 enzymes is induced by St. John's Wort which reduces the effectiveness of several medications such as antidepressants and oral contraceptives (Brewer and Chen, 2017).

Standardization process is necessary for guaranteeing consistency in herbal medicines (Garg et al., 2012). Diversity in plant species, growing environment and conditions, harvesting time, and extraction methods can have impact on the concentration of bioactive compounds (Patel, 2020). There are new techniques which include chromatographic

profiling (Balekundri and Mannur, 2020), DNA barcoding for species (Noviana et al., 2022) and taxonomic identification, and metabolic phenotyping. These are involved in the improvement of quality control and ensure therapeutic dependence.

MECHANISTIC INSIGHTS OF HERBAL BIO-ACTIVES

Therapeutic effects are regulated by phytochemicals via many molecular interactions. Flavonoids like quercetin and kaempferol impede NF- κ B and MAPK pathways which cause a reduction in inflammation and oxidative stress (Al-Khayri et al., 2022). Terpenoids including artemisinin and ursolic acid activate programmed cell death through the release of mitochondrial cytochrome c (Zhang et al., 2018). Alkaloids such as berberine (Xiong et al., 2022) Vincristine affects cell proliferation by binding to DNA or tubulin (Majrashi et al., 2023). Polyphenols modulate non genetic mechanisms and increase nitric oxide formation ameliorating endothelial function (Yamagata, 2019). Saponins change the membrane penetrability and metabolism of cholesterol (Marrelli et al., 2016). The composite synergy permits herbal preparations to rectify several poorly regulated pathways simultaneously which is an advantage over single target synthetic molecules (Gertsch, 2011).

Standardization and quality control

Consistency is one of the biggest challenges for herbal drugs. Variation emerges from the genetic makeup of plants, conditions of harvesting, and the methods of extraction (Wang et al., 2023). The guidelines of the World Health Organization (WHO) for Quality Control of Herbal Medicines endorse fingerprint characterization using HPLC, LC-MS, or DNA barcoding (Noviana et al., 2022). Standardization based on the Marker guarantee batch-to-batch reproducibility comparable to synthetic drugs (Organization, 2017). Heavy metals, pesticides, and adulterants are contaminants that must be computed to observe the pharmacopeial limits (Steinhoff, 2021). The adoption of Good Agricultural and Collection Practices (GACP) and Good Manufacturing Practices (GMP) is requisite for approval of regulators in many jurisdictions.

GLOBAL REGULATORY FRAMEWORK AND MARKET TRENDS

Regulation of herbal medicines differs globally. Herbal Medicinal Products Directive 2004/24/EC needs 30 years of traditional use (15 in EU) for simplified registration as per the European Union (Ernst, 2004). In the United States these are classified as Dietary Supplements under the Dietary Supplement Health and Education Act of 1994 as manufacturers make sure of safety but not efficacy (Act, 1994). China and India have consolidated systems where Traditional Chinese Medicine and Ayurveda are officially acknowledged (Hu, 2021). Traditional Unani and herbal products are entered under the National Council for Tibb in Pakistan. The international herbal exchange surpassed US \$150 billion in 2024 with an estimated Compound Annual

Growth Rate, CAGR, greater than 6 %. Consumer preference for natural wellness and green pharmacology are chief growth driver (Hu, 2021).

CHALLENGES AND FUTURE DIRECTIONS

Despite the fact that herbal alternatives confine promising potential, until now they have confronted various challenges that restrict their extensive use (Parveen et al., 2015). Numerous conventional therapies require strong scientific validation through well planned double-blind clinical trials (Koonrungsomboon et al., 2024). It is also difficult to understand how different compounds interact and act in the body because of their complex, multi-component nature (Liu et al., 2013). Another existing major obstacle is obtaining rational property rights for natural molecules, while variations in chemical constitution across plant sources impede the process of standardization and quality assurance (Harrison, 2014). Combining these natural therapies with modern medicine requires well-balanced, practical combination approaches (Zhang et al., 2022).

Moving forward, research should highlight advanced areas. Current inventions are remodeling the discovery, standardization, formulation and validation of herbal products. Since crude plant extracts comprise of large number of metabolites, methods that increase resolution (metabolomics), forecast bioactivity, unfold multi-target mechanisms (network pharmacology), and upgrade delivery and bioavailability (nanotechnology) are crucial to interpret traditional knowledge into scalable, clinically functional phytopharmaceuticals (Salem et al., 2020).

Artificial intelligence (AI) and models of machine learning speed up the discovery and arrangement of large phytochemical databases. These techniques consist of, ligand-based ML (machine learning) models which are instructed on familiar bioactive plant compounds, in silico screening of structure and docking against disease targets, and NLP (natural language processing) extraction of literature and herbarium records to identify promising species. According to initial studies, AI can specify the collection of possible candidates and propose complementary pairings for investigational authentication, which is an important efficiency uplift when controlling the diversity of botanical chemicals. Limitations include biased training sets and the requirement for exceptionally well labelled data (Almatroudi, 2024).

REFERENCES

- Abdul-Aziz MH, JWC Alfenaar, M Bassetti et al., 2020. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. *Intensive care medicine* 46:1127.
- Act A, 1994. Dietary Supplement Health and Education Act of 1994 Public Law 103-417 103rd Congress. Public Law 103: 417.
- Al-khayri JM, GR Sahana, P Nagella et al., 2022. Flavonoids as potential anti-inflammatory molecules: A review. *Molecules* 27:2901.
- Almatroudi A, 2024. Integrative machine learning, virtual screening, and molecular modeling for BacA-Targeted Anti-Biofilm drug discovery against Staphylococcal infections. *Crystals* 14:1057.
- Aus Der Beek T, FA Weber, A Bergmann et al., 2016. Pharmaceuticals in the environment—Global occurrences and perspectives. *Environmental toxicology and chemistry* 35:823-35.
- Ayustaningwaarno F, G Anjani, AM Ayu et al., 2024. A critical review of Ginger's (*Zingiber officinale*) antioxidant, anti-inflammatory, and immunomodulatory activities. *Frontiers in nutrition* 11:1364836.
- Balekundri A and V Mannur, 2020. Quality control of the traditional herbs and herbal products: a review. *Future Journal of Pharmaceutical Sciences* 6:67.
- Bhaattaram VA, U Graefe, C Kohlert et al., 2002. Pharmacokinetics and bioavailability of herbal medicinal products. *Phytomedicine* 9:1-33.
- Brewer CT and T Chen, 2017. Hepatotoxicity of herbal supplements mediated by modulation of cytochrome P450. *International Journal of Molecular Sciences* 8:2353.
- Dimasi JA, HG Grabowski and RW Hansen, 2016. Innovation in the pharmaceutical industry: new estimates of RandD costs. *Journal of health economics* 47:20-33.
- El-Khoury C, E Mansour, Y Yuliandra et al., 2022. The role of adjuvants in overcoming antibacterial resistance due to enzymatic drug modification. *RSC Medicinal Chemistry* 13:1276-99.
- Ernst E, 2004. Risks of herbal medicinal products. *Pharmacoeconomics and drug safety* 13:767-71.
- Fabricant DS and NR Farnsworth, 2001. The value of plants used in traditional medicine for drug discovery. *Environmental health perspectives* 109:69-75.
- Garg V, VJ Dhar, A Sharma et al., 2012. Facts about standardization of herbal medicine: a review. *Zhong xi yi jie he xue bao= Journal of Chinese integrative medicine* 10:1077-1083.
- Gertsch J, 2011. Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. *Planta medica* 77:1086-98.
- Gómez Afonso A, D Fernandez-Lazaro, DP Adams et al., 2023. Effects of *Withania somnifera* (Ashwagandha) on hematological and biochemical markers, hormonal behavior, and oxidant response in healthy adults: a systematic review. *Current Nutrition Reports* 12:465-77.
- Gurley BJ, 2025. Clinically relevant herb–drug interactions: a 30-year historical assessment. *Journal of Dietary Supplements* 22:78-104.
- Harrison C, 2014. Patenting natural products just got harder. *Nature Biotechnology* 32:403-405.
- Hawks MK, PF Crawford, DA Moss et al., 2021. Integrative Medicine: Herbal Supplements. *FP essentials* 505:23-27.
- Hu Q, 2021. The regulation of Chinese medicine in China. *Longhua Chinese Medicine* 4.
- Huang J, M Zaynab, Y Sharif et al., 2024. Tannins as antimicrobial agents: Understanding toxic effects on pathogens. *Toxicon* 247:107812.
- Jo DM, KJ Cho, N Tabassum et al., 2025. Understanding the role of drug efflux pumps in biofilms and virulence properties: multiple potential strategies controlling bacterial infections. *International Journal of Antimicrobial Agents* 50:86-94.
- Karimi A, M Majlesi and M Rafeian-Kopaei, 2015. Herbal versus synthetic drugs; beliefs and facts. *Journal of nephropharmacology* 4:27.
- Kaur G, P Rana, V Dwibedi et al., 2024. Herbal or Poly-Herbal Formulations in Various Viral Diseases. *Promising Antiviral Herbal and Medicinal Plants CRC Press*, pp: 348 ISBN: 9781003329169
- Kazmi Koonrungsomboon N, C Sakuludomkan, M Na Takuathung et al., 2024. Study design of herbal medicine clinical trials: a descriptive analysis of published studies investigating the effects of herbal medicinal products on human participants. *BMC complementary medicine and therapies* 24:391.
- Kumar APN, M Kumar, A Jose et al., 2023. Major phytochemicals: recent advances in health benefits and extraction method. *Molecules* 28:887.
- Lazarou J, BH Pomeranz and PN Corey, 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *Jama* 279:1200-05.
- Lee JY, SA Jun, SS Hong et al., 2016. Systematic review of adverse effects from herbal drugs reported in randomized controlled trials. *Phytotherapy Research* 30:1412-19.
- Lee M, H Shin, M Park et al., 2022. Systems pharmacology approaches in herbal medicine research: a brief review. *BMB reports* 55:417.
- Li C, WW Jia, JL Yang, et al., 2022. Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines. *Acta Pharmacologica Sinica* 43:3080-3095.
- Liu H, J Wang, W Zhou et al., 2013. Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. *Journal of ethnopharmacology* 146:773-93.
- Majrashi TA, SA Alshehri, A Alsayari et al., 2023. Insight into the biological roles and mechanisms of phytochemicals in different types of cancer: targeting cancer therapeutics. *Nutrients* 15:1704.
- Maarrelli M, F Conforti, F Araniti et al., 2016. Effects of saponins on lipid metabolism: A review of potential health benefits in the treatment of obesity. *Molecules* 21:1404.

- Mujahid MH, TK Upadhyay and VJ Upadhye, 2024. Targeted identification of antibacterial phytochemicals from plant extracts against multidrug-resistant bacteria: a systematic review. *Integrative Biomedical Research* 8:1-18.
- Newman DJ and GM Cragg, 2020. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *Journal of natural products* 83:770-803.
- Nissen M, 2022. Factors responsible for increased use of herbal medicines and self-medication. *Advances in Pharmacoepidemiology and Drug Safety* 11:10-11.
- Noviana E, G Indraayanto and A Rohman, 2022. Advances in fingerprint analysis for standardization and quality control of herbal medicines. *Frontiers in Pharmacology* 13:853023.
- O'Neil PM, VE Barton and SA Ward, 2010. The molecular mechanism of action of artemisinin—the debate continues. *Molecules* 15:1705-21.
- Organization WH, 2017. WHO guidelines for selecting marker substances of herbal origin for quality control of herbal medicines. WHO Technical Report Series.
- Parveen A, B Parveen, R Parveen et al., 2015. Challenges and guidelines for clinical trial of herbal drugs. *Journal of Pharmacy and Bioallied Sciences* 7:329-33.
- Patel SK, 2020. Standardization of Herbal Drugs: Challenges and Current Practices in Pharmacognosy. *Innovations in Pharmacy Planet* 8: 34-36.
- Rausch H, S Schröder, T Friedemann et al., 2024. History and present of European traditional herbal medicine (Phytotherapy). History, Present and Prospect of World Traditional Medicine. World Scientific, pp: 131-234. ISBN: 9789811287107.
- Rombolá L, D Scuteri, S Marilisa et al., 2020. Pharmacokinetic interactions between herbal medicines and drugs: their mechanisms and clinical relevance. *Life* 10:106.
- Roy D, M Ghosh and NK Rangra, 2024. Herbal Approaches to Diabetes Management: Pharmacological Mechanisms and Omics-Driven Discoveries. *Phytotherapy Research* 38
- Salem MA, L Perez De Souza, A Serag et al., 2020. Metabolomics in the context of plant natural products research: From sample preparation to metabolite analysis. *Metabolites* 10:37.
- Series I, 2024. Futuristic Trends in Herbal Medicines and Food Products, pp: 70-97. ISBN: 978-93-5747-680-5
- Shahcheraghi SH, F Salemi, S Small et al., 2023. Resveratrol regulates inflammation and improves oxidative stress via Nrf2 signaling pathway: Therapeutic and biotechnological prospects. *Phytotherapy Research* 37:1590-1605.
- Shahrajabian MH and W Sun, 2024. The golden spice for life: turmeric with the pharmacological benefits of curcuminoids components, including curcumin, bisdemethoxycurcumin, and demethoxycurcumins. *Current organic synthesis* 21:665-83.
- Shao-Ling W, L Ying, W Ying et al., 2009. Curcumin, a potential inhibitor of up-regulation of TNF-alpha and IL-6 induced by palmitate in 3T3-L1 adipocytes through NF-kappaB and JNK pathway. *Biomedical and Environmental Sciences* 22:32-39.
- Shoba G, D Joy, T Joseph et al., 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta medica* 64:353-56.
- Singh N, A Gusain, M Nigam et al., 2025. The pharmacological and therapeutic versatility of Allium species: a comprehensive exploration of bioactive constituents and biological activities. *Discover Applied Sciences* 7:349.
- Steinhoff B, 2021. Challenges in the quality of herbal medicinal products with a specific focus on contaminants. *Phytochemical Analysis* 32:117-23.
- Stevenson LM, A Matthias, L Banbury et al., 2005. Modulation of macrophage immune responses by Echinacea. *Molecules* 10:1279-85.
- Stratton CF, DJ Newman and DS Tan, 2015. Cheminformatic comparison of approved drugs from natural product versus synthetic origins. *Bioorganic and medicinal chemistry letters* 25:4802-07.
- Sun L, Q Yu, F Peng et al., 2024. The antibacterial activity of berberine against Cutibacterium acnes: its therapeutic potential in inflammatory acne. *Frontiers in Microbiology* 14:1276383.
- Szumilak M, A Wiktorowska-Owczarek and A Stanczak, 2021. Hybrid drugs—a strategy for overcoming anticancer drug resistance? *Molecules* 26:2601.
- Thamizhoviya G, 2025. Global Integration of Traditional and Modern Medicine: Policy Developments, Regulatory Frameworks, and Clinical Integration Model. *Future Integrative Medicine* 4:180-90.
- Tillhon M, LMG Ortiz, P Lombardi et al., 2012. Berberine: new perspectives for old remedies. *Biochemical pharmacology* 84:1260-67.
- Wang H, Y Chen, L Wang et al., 2023. Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. *Frontiers in pharmacology* 14:1265178.
- Wang X, X Xu, W Tao et al., 2012. A systems biology approach to uncovering pharmacological synergy in herbal medicines with applications to cardiovascular disease. *Evidence-Based Complementary and Alternative Medicine* 2012:519031.
- Xiao MY, S Li, WJ Pei et al., 2025. Natural Saponins on Cholesterol-Related Diseases: Treatment and Mechanism. *Phytotherapy Research* 39:1292-1318.
- Xiong RG, SY Huang, SX Wu et al., 2022. Anticancer effects and mechanisms of berberine from medicinal herbs: an update review. *Molecules* 27: 4523.
- Yamagata K, 2019. Polyphenols regulate endothelial functions and reduce the risk of cardiovascular disease. *Current pharmaceutical design* 25:2443-58.
- Yang WS, D Jeong, YS Yi et al., 2013. IRAK1/4-targeted anti-inflammatory action of caffeic acid. *Mediators of Inflammation* 2013:51818
- Zeien J, W Qiu, M Triay et al., 2022. Clinical implications of chemotherapeutic agent organ toxicity on perioperative care. *Biomedicine and Pharmacotherapy* 146:112503.
- Zhang Y, CM Ip, YS Lai et al., 2022. Overview of current herb–drug interaction databases. *Drug Metabolism and Disposition* 50:86-94.
- Zhang Y, G Xu, S Zhang et al., 2018. Antitumor research on artemisinin and its bioactive derivatives. *Natural products and bioprospecting* 8:303-19.
- Zheng D, T Liu, S Yu et al., 2024. Antimalarial mechanisms and resistance status of artemisinin and its derivatives. *Tropical Medicine and Infectious Disease* 9:223.